Ochsner Health and Paradigm Health Expand Access to Clinical Trials Across the Gulf South.

Ochsner Health, the Gulf South's important nonprofit academic medical care technology, and Paradigm Health, an AI-based clinical trial organization, announced the launch of a system-driven collaboration intended to increase access to clinical trials in Ochsner's patient population. Paradigm Health's AI-based recruitment platform reviews and identifies potential trial patients in the 47 Ochsner hospitals and 370 medical care centers, increasing Ochsner patients' access to trials by 41%.

Clinical trials provide patients with important treatment choices and renewed hope. With many trial sites throughout Louisiana, Ochsner had a strong foundation to increase participation in its network and connect more patients to research opportunities closer to home. To support this growth, Paradigm Health introduced an effective way to assess patient eligibility across a large population by having secondary research staff review the review process.

Ochsner implemented Paradigm Health's AI-powered patient recruitment platform, which incorporates electronic health records and other clinical information sources to continuously evaluate a patient's healthcare record against clinical trial suitability criteria. By applying AI-driven technology to efficiently and precisely evaluate a patient's eligibility, Ochsner can continuously reassess a wide group of patients as they progress through their care journey and incorporate trial recruitment into routine patient visits, making it easier for patients to learn about trials and consider enrollment as part of their hands-on care with clinicians.

Deployment of this LLM-driven platform has yielded meaningful results for both Ochsner's patients and healthcare research staff:

• 41% increase in screening capacity: By increasing the reach of Ochsner's clinical research team, the platform increased the number of patients clinically considered for trial participation, helping ensure eligible patients were not overlooked.
• 3.6x increase in patients identified for future trial eligibility: By continuously reviewing patient information, the platform recognized patients who were not yet eligible for a clinical trial but could become qualified as they progress through their care journey. This allows research teams to reassess eligibility in near real time without additional administrative load.
• 75% reduction in manual effort: AI-driven patient identification and continuous suitability screening reduced the substantial physical effort needed by healthcare research coordinators to identify and review potentially eligible patients. The LLM-native eligibility assessment allowed healthcare staff to review eligibility of the most likely candidates only and spend more time directly engaging and helping patients with trial enrollment.

"This partnership has helped us implement a more comprehensive, integrated perspective of our patients' eligibility for trials that extends past individual clinics or specific healthcare encounters," said Nneka Ifejika, MD, chief scientific officer at Ochsner Health. "By pinpointing eligible patients sooner in their treatment path and tracking changing eligibility status, we are making our clinical trial infrastructure more efficient and expanding the reach of Ochsner's research team to consider and enroll more patients in need of trials as a care option."

"Our partnership with Paradigm Health marks a fundamental shift in how we approach clinical research," said Wendy Chriss, PhD, director of clinical research at Ochsner Health. "By automating the incredibly complex, manual screening process, we are making clinical trials an inclusive, realistic care option for more patients across the Gulf South. This isn't just an operational victory; it is a major step forward in our region."

"The traditional clinical trial model leaves out the vast majority of Americans who receive care in community settings, and we have built AI-enabled infrastructure to address this challenge," said Kent Thoelke, founder and CEO of Paradigm Health. "Through our work with Ochsner, we are proving that when we embed intelligent infrastructure directly into a provider's existing workflow, we can scale trial access rapidly, alleviate coordinator burnout, and ultimately accelerate the delivery of life-saving treatments to market."

According to Towards Healthcare, the clinical trials support software solutions market is projected to grow significantly, with estimates indicating the market size will increase from USD 14.31 billion in 2026 to approximately USD 34.15 billion by 2035, expanding at a CAGR of 10.15% from 2026 to 2035. Clinical trial management software offers major operational efficiencies-from cost control to rapid completion of the trial-resulting in a plethora of advantages for both clinical research sponsors and organizations. Robotics in CTMS eliminates significant entry errors, reducing the error rate and saving the precious time of healthcare groups to concentrate their resources on more strategically significant tasks driving the aim of the research. It involves built-in compliance features such as FDA 21 CFR Part 11 and GDPR that prevent the imposition of penalties and fines and store data safely with access control based on confidentiality.

About Ochsner Health

The Gulf South's premier nonprofit academic medical care technology, Ochsner Health, offers specialized healthcare services via a network of 47 hospitals and over 370 clinics and urgent care solutions. Nationally recognized for its commitment to healthcare excellence and digital innovation, Ochsner served 1.6 million individuals from across the globe in 2025, reinforced by a dedicated team of 40,000 employees and 5,000 doctors.

About Paradigm Health

Paradigm Health has engineered an AI-driven platform to make clinical trials more accessible and effective, so that patients, investigators, and research sponsors can increase the impact of clinical research. Incubated by ARCH Venture Partners and backed by leading medical care and life sciences investors, Paradigm Health aims to break down challenges in the trial ecosystem via one seamless infrastructure implemented at medical care provider organizations, bringing potentially life-saving therapies to patients more quickly.

A recent report by Towards Healthcare highlights that the clinical trial support software solutions market is growing, as clinical trial software plays a significant role in enhancing trial processes, thus leading to healthier trial performance. It streamlines a multitude of tasks like patient recruitment, trial planning, information collection, and analysis. These devices automate repetitive tasks, which are generally time-consuming, and enable researchers to focus more on the substantive aspects of the trial. It also fosters a seamless workflow, providing rapid access to healthcare research data and speeding up decision-making. Clinical trial software fosters seamless collaboration among different stakeholders involved in a clinical trial, involving researchers, clinicians, sponsors, and patients. It offers a centralized digital platform where all parties communicate, share relevant data, and work collaboratively towards common goals.